{"id":"W4417004071","doi":"10.1182/blood-2025-1800","title":"Promising response rates and manageable safety with mosunetuzumab plus lenalidomide (Mosun-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): US extension cohort from the Phase III CELESTIMO study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Lenalidomide; Follicular lymphoma; Cohort; Adverse effect; Rituximab; Common Terminology Criteria for Adverse Events; Cytokine release syndrome; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003473591,0.0003491835,0.0007345193,0.0002586719,0.0004051539,0.0009177314,0.0003479115,0.0004147823,0.001410631],"category_scores_gemma":[0.002206005,0.0001864082,0.0008302661,0.0003599295,0.0002866744,0.0005758462,0.0003490169,0.001170644,0.0003968944],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005401302,"about_ca_system_score_gemma":0.0009288418,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009758273,"about_ca_topic_score_gemma":0.002150509,"domain_scores_codex":[0.999131,0.0004083175,0.0000793418,0.0001270294,0.0001454026,0.0001089049],"domain_scores_gemma":[0.998495,0.0002904247,0.0003203415,0.0002526005,0.000206677,0.0004350684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3442916,0.01886769,0.3505099,0.0003866898,0.001969998,0.0003933931,0.0008687947,0.001614367,0.03148732,0.0002383279,0.009905041,0.2394668],"study_design_scores_gemma":[0.07672686,0.2413484,0.6443086,0.00009625949,0.002779423,0.002129,0.0005207147,0.003861236,0.0118063,0.0004019194,0.01592037,0.0001009079],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964078,0.0008681436,0.0002527135,0.0001617095,0.0000206143,0.0002922782,0.000896362,0.00003285776,0.001067471],"genre_scores_gemma":[0.9966618,0.0002197398,0.0004340696,0.0002182615,0.0000418844,0.0002143883,0.001772877,0.0000102884,0.0004266489],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003473591,"threshold_uncertainty_score":0.01837033,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006508503620268719,"score_gpt":0.241098801781042,"score_spread":0.2345902981607733,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}